Miridesap

Research use only, not for human use.

Miridesap (Ro 638695;GSK-2315698;CPHPC) is a competitive inhibitor of serum amyloid P component (SAP) binding to amyloid fibrils.

Miridesap (Ro 638695;GSK-2315698;CPHPC) is a competitive inhibitor of serum amyloid P component (SAP) binding to amyloid fibrils; crosslinks and dimerizes SAP molecules, leading to their very rapid clearance by the liver, and thus produces a marked depletion of circulating human SAP; Miridesap is a novel therapeutic approach to both systemic amyloidosis and diseases associated with local amyloid, including Alzheimer's disease and type 2 diabetes.Alzheimer Disease Phase 2 Clinical(In Vitro):Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles. Miridesap depletes circulating SAP almost completely but leaves some SAP in amyloid deposits for specific recognition by subsequently administered therapeutic anti-SAP antibodies.

Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles. Miridesap depletes circulating SAP almost completely but leaves some SAP in amyloid deposits for specific recognition by subsequently administered therapeutic anti-SAP antibodies.

——

Ro 638695 | GSK-2315698 | CPHPC

Others

Amyloids

Amyloids

Neurological Disease

Alzheimer Disease

224624-80-0

340.376

C16H24N2O6

>98% (HPLC)

DMSO : 75 mg/mL 220.35 mM

O=C(N1[C@H](CCC1)C(O)=O)CCCCC(N2[C@H](CCC2)C(O)=O)=O

1,1'-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

(-20℃)

With Ice Pack

≥ 2 years